NASDAQ$ANIK

Anika Therapeutics Inc · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Anika's second quarter performance was solid and the company is on track for achieving its stated full year guidance.

Anika Therapeutics reported solid second quarter results, with continued momentum in their regenerative solutions portfolio. The company received FDA 510(k) clearance for their X-Twist Fixation System and is on track for a limited market release in the second half of the year.

  • Second quarter revenue growth was up 4%.
  • X-Twist 510(k) clearance was received.
  • Limited market release of X-Twist is on schedule for the second half of 2022.
  • The company is on track for achieving its stated full year guidance.

Headline financials

Total Revenue

$39.7M

Previous: $38.1M+4.0%
EPS (adj)

-$0.12

Previous: $0.09-233.3%
Capital Expenditures

-$3.27M

Previous: -$2.73M-19.5%
Free Cash Flow

-$6.11M

Previous: $3.8M-260.8%
Net Income

-$2.84M

Previous: $6.53M-143.5%
Operating Income

-$3.38M

Previous: $9.18M-136.8%
Gross Profit

$24.9M

Previous: $20.8M+19.5%
Cash & Equivalents

$91.4M

Previous: $97.2M-6.0%
Total Assets

$354M

Previous: $363M-2.5%
Stock-Based Comp

$4.08M

Previous: $2.8M+45.9%

Revenue & EPS history

Anika · Revenue · Quarterly

$39.7M

Q2 2022+4%vs Q2 2021
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Forward guidance

The Company continues to expect its overall revenue for fiscal year 2022 to be toward the upper end of its guidance range of low to mid-single digit percent growth compared with 2021. There remains volatility and uncertainty in the global macroeconomic environment and the Company’s outlook for fiscal 2022 is subject to the changing dynamics associated with staffing shortages, supply chain disruption, inflation and other direct and indirect impacts of the COVID pandemic.

Headwinds

  • Staffing shortages
  • Supply chain disruption
  • Inflation
  • Direct and indirect impacts of the COVID pandemic
  • Volatility and uncertainty in the global macroeconomic environment

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

+0.1%

Avg return

Earnings day

-3.0%

Avg return

5 days after

-2.8%

Avg return

30 days after

51%

33 / 65 earnings

Positive

+32.1%

Q3 2019

Best reaction

-33.0%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-18.8%-4.7%-4.8%
Q4 2025+16.8%+31.6%+30.5%
Q3 2025+0.8%-0.5%+2.1%
Q1 2025-20.7%-23.2%-23.0%
Q4 2024-11.1%-7.3%-20.3%
Q3 2024-33.0%-34.0%-28.2%
Q2 2024-1.0%-3.6%-5.4%
Q1 2024-10.9%-9.9%-9.1%
Q4 2023-4.8%-2.0%-3.1%
Q3 2023+7.4%+6.7%+15.2%
Q2 2023-4.9%-12.7%-18.0%
Q1 2023-2.8%-3.2%+3.2%
Q4 2022-18.0%-17.4%-10.4%
Q3 2022+0.3%+5.3%+6.3%
Q2 2022-4.9%-2.7%-6.0%
Q1 2022-4.9%-3.8%+1.1%
Q4 2021-15.9%-18.0%-20.1%
Q3 2021+3.1%-8.2%-12.8%
Q2 2021+1.0%+0.8%+1.3%
Q1 2021+1.3%+2.8%+10.9%
Q4 2020-10.5%-12.1%+3.9%
Q3 2020-3.3%+0.2%+7.6%
Q2 2020+0.3%-8.7%+2.9%
Q1 2020-9.9%-12.2%+9.1%
Q4 2019+0.4%+0.1%-39.5%
Q3 2019+32.1%+21.5%+3.7%
Q2 2019+29.1%+31.0%+37.2%
Q1 2019+19.6%+21.5%+15.9%
Q4 2018-15.3%-18.8%-26.5%
Q3 2018-11.0%-13.6%-13.9%
Q2 2018+18.6%+15.0%+20.8%
Q1 2018-22.9%-15.7%-8.6%
Q4 2017-4.0%-11.3%-17.4%
Q3 2017-8.0%-9.2%-8.0%
Q2 2017+7.1%+6.0%+9.3%
Q1 2017-5.5%-1.8%+0.4%
Q4 2016-5.0%-5.1%-16.4%
Q3 2016+2.0%+2.7%+8.0%
Q2 2016-5.0%-2.3%-6.7%
Q1 2016+0.5%
Q4 2015+11.2%
Q3 2015+12.5%
Q2 2015+3.2%
Q1 2015-7.5%
Q4 2014-10.7%
Q3 2014+1.0%
Q2 2014+4.1%
Q1 2014+7.7%
Q4 2013+26.9%
Q3 2013+6.5%
Q2 2013+21.9%
Q1 2013-1.8%
Q4 2012+16.6%
Q3 2012-7.7%
Q2 2012+24.4%
Q1 2011+0.6%
Q1 2012+2.8%
Q4 2009+1.5%
Q4 2011+1.5%
Q3 2011+7.0%
Q3 2010+7.0%
Q2 2010-3.4%
Q4 2010-3.4%
Q2 2011-3.4%
Q1 2010-1.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro